The New Partnership for African’s Development (NEPAD) is a technical body of the African union with a main objective of facilitating and coordinating Africa’s development agenda. NEPAD’s mandate includes contributing to the attainment of the Pharmaceutical Manufacturing Plan for Africa (PMPA), Agenda 2063, and SDGs (among others).
The NEPAD Agency serves in the PAVIA Board. The NEPAD Agency also coordinates the AMRH Programme which is aligned to the PAVIA Project in terms of the goals for access to quality, safe and efficacious medical products.
NEPAD is a key part of the AMRH Governance framework (and it is worth noting that among the proposed Technical working groups under this framework is one on Pharmacovigilance). Under this framework an independent scientific Safety Advisory Committee is also proposed. NEPAD has initiated REC level platforms and guidelines that includes (among others) Review/inclusion of PV in policy and regulations across the East Africa Community( EAC) )and partner states, inclusion of PV in harmonized health professional training curricula and greater involvement of National Medicines Regulatory Authority (NMRAs) and PV stakeholders. NEPAD’s work on PV focuses at the continental and regional levels; PAVIA and PROFORMA could play a welcome role in supporting implementation at national level.
The activities in PAVIA are organized along 5 work packages in which our 13 partners adopt a collaborative approach in reaching our objectives. Through alignment with relevant global and regional initiatives such as AMA (African Medicines Agency) and NEPAD (New partnership for Africa’s Development) it is ensured through their representation on the PAVIA Advisory Board. At the end of the project, PAVIA will deliver a blueprint for strengthening the medication regulatory process which can be implemented across other Sub-Sahara African countries, ultimately making medications safer for patients across the continent. More about NEPAD can be found on their website.